Pipeline
Forest small banner

Glycostem’s pipeline has the potential to redefine standards of care across various type of cancer where there is an urgent medical need.

Therapy

Indication

Development

Pre-clinical

Phase I

Phase II

Phase III

Market Introduction

Partner

oNKord®

Blood Cancer -
Acute Myeloid Leukemia

color

color

color

Q2 2020

2nd half 2023

US: Glycostem; EU: Glycostem;
JP: undisclosed; KR: undisclosed

oNKord®

Blood Cancer -
Multiple Myeloma

color

color

color

Q1 2021

2nd half 2023

US: Glycostem; EU: Glycostem;
JP: undisclosed; KR: undisclosed

oNKord®

Solid Tumors -
Investigational pre-conditioning
(Investigator Initiated Trial)

color

TBA

oNKord®

Solid Tumors -
Adjuvant post-surgery
with alternative pre-conditioning

color

TBA

Therapy

Indication

Development

Pre-clinical

Phase I

Phase II

Phase III

Market introduction

Partner

CAR-NK

Colorectal Cancer

color

color

TBA

Glycostem

CAR-NK

Leukaemia

color

color

TBA

Glycostem

CAR-NK

Glioblastoma

color

color

TBA

Undisclosed

Therapy

Indication

Development

Pre-clinical

Phase I

Phase II

Phase III

Market introduction

Partner

TCR-NK

Early stage, tbd

color

color

TBA

Zelluna